Principles of Chemotherapy

Chemotherapy is one of the few branches of medicine where the goal is deliberately to poison the patient — just enough, and just selectively enough, to kill the cancer while letting the person recover. That razor-thin margin between tumour cell death and host survival is the whole story of oncology pharmacology. Understanding it means understanding how cancer cells divide, where in the cell cycle drugs strike, why tumours eventually stop responding, and why a patient's hair falls out and blood counts drop. This page teaches the logic that ties all of that together, so that a drug list becomes a coherent framework rather than a set of names to memorise.

Learning Objectives

• Explain the cell cycle and how cytotoxic drug classes are timed to specific phases.
• Distinguish cytotoxic ("classical") chemotherapy from targeted therapy and immunotherapy by mechanism.
• Describe the log-kill hypothesis and the rationale for combination regimens and dose intensity.
• List the major mechanisms of acquired and intrinsic drug resistance.
• Predict and categorise dose-limiting and delayed toxicities from a drug's mechanism.
• Recount the historical arc from wartime mustard gas to the first cures of childhood leukaemia and why it reshaped medicine.

Quick Answer

Chemotherapy exploits the fact that cancer cells divide more, and repair damage less faithfully, than most normal cells. Classical cytotoxic drugs damage DNA or block its synthesis, mitosis, or the machinery of cell division; because dividing cells are most vulnerable, the drugs also hit normal fast-turnover tissues (marrow, gut lining, hair follicles), producing the familiar toxicities. Killing follows first-order (log-kill) kinetics — a given dose kills a constant fraction, not a constant number, of cells — which is why treatment is repeated in cycles and drugs are combined. Targeted agents instead block a specific molecular driver (a mutated kinase, a receptor, a repair pathway) and are generally less toxic to bystander tissues but limited to tumours carrying that target. Resistance — through drug efflux, target mutation, enhanced repair, or apoptosis evasion — is the central reason cures remain elusive in advanced disease. The field was born from the accidental discovery that mustard gas suppressed bone marrow, leading within two decades to the first true cures of a disseminated cancer, childhood acute leukaemia.

Where It Came From

The origin of chemotherapy is a rare instance of medicine emerging directly from the horror of chemical warfare. In World War I, soldiers exposed to sulphur mustard ("mustard gas") were found at autopsy to have profoundly depleted bone marrow and lymphoid tissue. The observation sat largely unused until World War II. After a 1943 accident in the Italian port of Bari, where an American ship carrying mustard agent was bombed, physicians again noted marrow and lymph node suppression in exposed survivors. Pharmacologists Louis Goodman and Alfred Gilman at Yale, working under a classified US government contract, reasoned that if the agent destroyed rapidly dividing lymphoid cells, it might destroy a lymphoid cancer. In 1942 they treated a patient with advanced lymphoma using intravenous nitrogen mustard; the tumour masses melted away — dramatically, if only temporarily. This was the first demonstration that a drug could shrink a solid human cancer, and it launched the entire discipline.

The deeper motivation, though, came from a disease that had no answer at all: childhood acute lymphoblastic leukaemia (ALL), which was uniformly and rapidly fatal. Sidney Farber, a pathologist in Boston, reasoned about the biochemistry of blood-cell production. Knowing that folic acid stimulated marrow proliferation, he hypothesised that a folate antagonist might starve leukaemic cells. In 1947–48, using aminopterin (a precursor of methotrexate), Farber produced the first temporary remissions in children with ALL — astonishing at the time, because the disease had been considered untouchable. Remissions still relapsed, and the children died, which taught the next hard lesson: single drugs do not cure.

The cure came from combining ideas. Emil Frei, Emil Freireich, and James Holland in the 1960s reasoned that, as with tuberculosis, using several drugs with different mechanisms and non-overlapping toxicities simultaneously might prevent resistant clones from emerging. Their VAMP and later POMP regimens, combined with the log-kill insight of Howard Skipper (that each cycle kills a fixed proportion of cells, so treatment must continue past apparent remission to eradicate hidden disease), produced the first durable cures of childhood ALL. By the 1970s a once-uniformly-fatal cancer became curable in the majority of children. That transformation — from a wartime poison to a genuine cure — is why the principles below matter.

The Cell Cycle and Phase Specificity

Understanding chemotherapy starts with the cell cycle, the ordered sequence a cell passes through to divide. It has four active phases plus a resting state:

• G1 (gap 1): the cell grows and prepares building blocks; a critical checkpoint decides whether to commit to division.
• S (synthesis): DNA is replicated, doubling the genome.
• G2 (gap 2): the cell checks the copied DNA and prepares for mitosis.
• M (mitosis): chromosomes separate and the cell physically divides.
• G0 (quiescence): a resting state outside the cycle; cells here are largely protected from cycle-active drugs.

Drugs are grouped by how their killing depends on this cycle:

Cell-cycle-phase-specific drugs work only when cells are in a particular phase. Antimetabolites (methotrexate, 5-fluorouracil, cytarabine, gemcitabine) act in S phase by masquerading as, or blocking synthesis of, the nucleotide building blocks of DNA. Vinca alkaloids (vincristine, vinblastine) and taxanes (paclitaxel, docetaxel) act in M phase by disrupting microtubules — vincas prevent their assembly, taxanes prevent their disassembly, both stalling mitosis. Because these drugs only kill cells passing through the vulnerable phase, they are most effective given by prolonged or repeated exposure, catching more cells as they cycle through.

Cell-cycle-nonspecific drugs damage cells in any phase, including some in G0, though dividing cells still suffer most because they cannot repair the damage before replication. The alkylating agents (cyclophosphamide, the direct descendants of nitrogen mustard) crosslink DNA strands. Platinum compounds (cisplatin, carboplatin) form similar DNA adducts. Anthracyclines (doxorubicin) intercalate DNA and poison topoisomerase II. These tend to show a steeper dose-response — bigger single doses kill more.

This phase logic is not academic: it dictates scheduling. A worked example — high-dose methotrexate for ALL is followed by leucovorin (folinic acid) rescue given at a precise interval. Methotrexate blocks dihydrofolate reductase, starving cells of the reduced folate needed for DNA synthesis in S phase. Leucovorin, a downstream reduced folate, is given later to rescue normal marrow and gut cells before they die, while tumour cells — which have accumulated more drug — are already committed. Timing is everything; giving leucovorin too early abolishes the antitumour effect, too late lets toxicity run away.

Log-Kill, Combinations, and Dose Intensity

Howard Skipper's mouse leukaemia experiments produced the single most important quantitative principle in chemotherapy: the log-kill hypothesis. A given dose of a drug kills a constant fraction of tumour cells, not a constant number, regardless of how many are present. If a dose kills 99.9% (3 logs) of a tumour of 10^10 cells, it leaves 10^7 — a clinically undetectable but far-from-cured population. This is why:

• Treatment is given in repeated cycles: each cycle knocks down the same fraction, driving the burden progressively lower.
• Treatment continues past apparent remission (consolidation and maintenance), because "remission" simply means the tumour has dropped below the detection threshold, not that it is gone.
• Dose intensity (dose per unit time) matters: reducing dose or delaying cycles reduces the fraction killed and can let the tumour regrow between cycles.

Combination chemotherapy — the insight that cured ALL and Hodgkin lymphoma (the MOPP regimen) — rests on three rules. Combine drugs that (1) are each active against the tumour alone, (2) have different mechanisms so resistant clones to one are still hit by another, and (3) have non-overlapping dose-limiting toxicities so each can be given at full dose. The Goldie–Coldman hypothesis refined this: tumours spontaneously generate drug-resistant mutants at a rate proportional to their size, so treatment should begin early and hit hard with multiple non-cross-resistant agents before resistant clones dominate.

Targeted Therapy and the Molecular Turn

Classical cytotoxics are indiscriminate; targeted therapies aim at a specific molecular lesion the cancer depends on. The paradigm case is imatinib in chronic myeloid leukaemia. CML is driven by the BCR-ABL fusion protein, a constitutively active tyrosine kinase produced by the Philadelphia chromosome. Imatinib occupies the kinase's ATP-binding pocket, switching off the growth signal. It transformed CML from a fatal disease into a chronic one managed with a daily pill — the proof of principle for the whole targeted era.

Categories to know:

• Small-molecule kinase inhibitors (names ending "-ib"): imatinib (BCR-ABL), erlotinib and osimertinib (EGFR in lung cancer), trastuzumab targets… (see below).
• Monoclonal antibodies (names ending "-mab"): trastuzumab against HER2 in breast cancer, rituximab against CD20 on B-cell lymphomas, bevacizumab against VEGF to starve tumour blood supply.
• Hormonal (endocrine) therapy: tamoxifen and aromatase inhibitors in oestrogen-receptor-positive breast cancer; androgen deprivation in prostate cancer.
• Immunotherapy: checkpoint inhibitors (against PD-1, PD-L1, CTLA-4) release the brakes on the patient's own T cells; CAR-T cells re-engineer a patient's T cells to recognise the tumour.

The trade-off: targeted agents spare most normal tissue and so avoid the marrow and gut toxicity of cytotoxics, but they only help patients whose tumour actually carries the target — hence the rise of companion diagnostics (HER2 testing, EGFR mutation testing, PD-L1 staining) that select who will benefit.

Drug Resistance

Resistance is why metastatic cancer is so often incurable, and it comes in two flavours: intrinsic (present before treatment) and acquired (emerging under selective pressure). Key mechanisms:

• Increased drug efflux: overexpression of P-glycoprotein (the MDR1 pump) exports many structurally unrelated drugs, causing "multidrug resistance."
• Altered or amplified target: point mutations in BCR-ABL (e.g. T315I) that block imatinib binding; amplification of dihydrofolate reductase against methotrexate.
• Enhanced DNA repair: upregulated repair of platinum adducts reduces cisplatin efficacy.
• Drug inactivation or reduced activation: increased glutathione conjugation; loss of the enzyme that activates a prodrug.
• Evasion of apoptosis: loss of p53 function or overexpression of anti-apoptotic proteins (BCL-2) means the damaged cell fails to trigger its own death.
• Reduced drug uptake: downregulation of the folate transporter limiting methotrexate entry.

Because resistant clones pre-exist and expand under pressure, combination therapy and early, dose-intense treatment (Goldie–Coldman) are the practical countermeasures.

Toxicity: Predictable from Mechanism

Cytotoxic side effects follow directly from hitting fast-dividing normal tissues:

• Myelosuppression (the most common dose-limiting toxicity): neutropenia (infection risk — febrile neutropenia is an emergency), thrombocytopenia (bleeding), anaemia. The nadir is typically 7–14 days after a cycle.
• Mucositis and diarrhoea: damage to the rapidly renewing gut epithelium.
• Alopecia: hair follicle cells are highly proliferative; usually reversible.
• Nausea and vomiting: partly central (chemoreceptor trigger zone), managed with 5-HT3 antagonists, NK1 antagonists, and dexamethasone.

Some toxicities are drug-specific and not shared by the class — these are high-yield:

Drug	Signature toxicity	Prevention/monitoring
Doxorubicin (anthracycline)	Cumulative cardiomyopathy	Track lifetime cumulative dose; monitor ejection fraction; dexrazoxane
Cisplatin	Nephrotoxicity, ototoxicity, peripheral neuropathy	Aggressive hydration; use carboplatin if renal risk
Bleomycin	Pulmonary fibrosis	Cumulative dose limit; lung function tests
Vincristine	Peripheral neuropathy (never intrathecal — fatal)	Dose cap; strict route labelling
Cyclophosphamide	Haemorrhagic cystitis	Hydration plus mesa (mesna)
Methotrexate	Nephrotoxicity, mucositis, hepatotoxicity	Leucovorin rescue; alkalinise urine; monitor levels

Two special emergencies: tumour lysis syndrome (massive cell death releasing potassium, phosphate, and urate, causing arrhythmia and renal failure — prevented with hydration, allopurinol, or rasburicase) and extravasation of vesicants like doxorubicin (tissue necrosis at the injection site).

Real-World Applications

Chemotherapy is used with different intents, and knowing the intent frames every decision. Curative intent applies where cure is realistic — childhood ALL, Hodgkin lymphoma, testicular cancer, some early breast cancers. Adjuvant therapy is given after surgery to eradicate micrometastatic disease below detection (the log-kill population), as in node-positive breast or colon cancer. Neoadjuvant therapy is given before surgery to shrink a tumour, making it operable or breast-conserving, and to test in-vivo drug sensitivity. Palliative chemotherapy in advanced disease aims to prolong life and relieve symptoms, explicitly weighing toxicity against quality of life — a conversation, not an algorithm. Beyond oncology wards, the same drugs (methotrexate, cyclophosphamide) are used at low doses in rheumatology and transplant medicine for their immunosuppressive effect, and understanding their toxicities matters to every clinician who prescribes them. All of this requires oncology specialist judgement and multidisciplinary review.

Common Mistakes

Mistake 1: "Chemotherapy kills a set number of cancer cells." It kills a constant fraction (log-kill). This misconception makes clinicians stop too early. Correction: because each cycle removes a proportion, undetectable residual disease persists after apparent remission, which is exactly why consolidation and maintenance exist.

Mistake 2: "Targeted therapy has no serious side effects." Targeted drugs avoid classical marrow/gut toxicity but have their own real hazards — trastuzumab cardiotoxicity, EGFR-inhibitor rash and diarrhoea, checkpoint-inhibitor autoimmune colitis, pneumonitis, and endocrinopathies that can be life-threatening. Correction: they trade the toxicity profile, they do not eliminate it.

Mistake 3: "A drop in tumour markers or imaging means the cancer is cured." Remission means below detection threshold, not eradication. Correction: judge cure by long-term disease-free survival, and continue planned treatment through remission rather than stopping at first response.

Mistake 4: "Higher dose is always better." Dose intensity matters, but toxicity is dose-limiting, and some drugs have hard cumulative ceilings (anthracycline cardiotoxicity, bleomycin lung, cisplatin kidney). Correction: the goal is maximum tumour kill within the tolerable therapeutic window, not maximum dose.

Comparison and Connections

Feature	Cytotoxic chemotherapy	Targeted therapy	Immunotherapy
Mechanism	Damages DNA/mitosis of dividing cells	Blocks a specific molecular driver	Activates the patient's immune system
Selectivity	Low — hits all fast-dividing cells	High — needs the target present	Variable; can affect normal tissue via autoimmunity
Typical toxicity	Marrow, gut, hair	On-target effects (rash, cardiac, etc.)	Autoimmune (colitis, thyroiditis, pneumonitis)
Needs biomarker?	Usually no	Yes (companion diagnostic)	Often (PD-L1, tumour mutational burden)
Example	Cyclophosphamide, cisplatin	Imatinib, trastuzumab	Pembrolizumab, CAR-T

These principles connect tightly to the underlying biology in Pharmacology (pharmacokinetics, drug metabolism) and Pathology (mechanisms of neoplasia and apoptosis). The management of neutropenic sepsis links to Infectious Diseases and emergency care.

Practice Questions

Recall

Q: Name the two microtubule-targeting drug classes and the opposite ways they disrupt mitosis. A: Vinca alkaloids (vincristine, vinblastine) prevent microtubule assembly; taxanes (paclitaxel, docetaxel) prevent microtubule disassembly. Both arrest cells in M phase.

Understanding

Q: Why must chemotherapy usually be continued after a patient enters complete remission? A: Because killing follows log-kill kinetics — each cycle removes a fixed fraction of cells. "Complete remission" only means the tumour burden has fallen below the detection threshold (roughly 10^9 cells), so a large residual population may remain. Consolidation and maintenance continue reducing that burden toward true eradication.

Application

Q: A child on high-dose methotrexate is given leucovorin 24 hours later. Explain the pharmacological logic. A: Methotrexate blocks dihydrofolate reductase, depleting reduced folate needed for S-phase DNA synthesis. Leucovorin is a downstream reduced folate that bypasses the block, "rescuing" normal marrow and gut cells. It is timed so tumour cells (which have taken up and retained more drug) remain committed to death while normal tissue recovers. Too-early rescue would abolish the antitumour effect.

Analysis

Q: A CML patient controlled on imatinib for three years develops a rising white count. Molecular testing shows a T315I mutation in BCR-ABL. Explain what has happened and how it illustrates a general principle. A: A resistant clone carrying a kinase-domain mutation (T315I) that prevents imatinib from binding its ATP pocket has emerged under selective pressure and expanded. This is acquired resistance by target alteration. It illustrates the Goldie–Coldman principle that resistant mutants pre-exist and expand, and clinically prompts switching to a later-generation inhibitor active against T315I (e.g. ponatinib).

FAQ

Why does chemotherapy make hair fall out but not affect, say, muscle? Because cytotoxics preferentially damage rapidly dividing cells. Hair follicle matrix cells divide constantly, so they are hit hard; mature muscle cells rarely divide, so they are largely spared. The same logic explains marrow and gut toxicity and why the effects are mostly reversible once treatment stops.

Is chemotherapy always given intravenously? No. Many drugs are oral (imatinib, capecitabine, temozolomide), some are intrathecal (methotrexate, cytarabine into the CSF for leukaemia — but never vincristine, which is fatal intrathecally), intravesical (into the bladder), or intraperitoneal. Route depends on the drug and the disease site.

If targeted drugs are more precise, why not always use them instead of chemotherapy? They only work if the tumour carries the specific target, and resistance develops readily. Many cancers have no clean druggable driver, and combinations of cytotoxics still achieve the best cures in diseases like lymphoma and testicular cancer. Increasingly the two are combined.

What is the difference between adjuvant and neoadjuvant chemotherapy? Adjuvant is given after the primary treatment (usually surgery) to eliminate undetectable micrometastases. Neoadjuvant is given before surgery to shrink the tumour, improve resectability, and test drug sensitivity in the living tumour.

Can chemotherapy cause a second cancer years later? Yes — alkylating agents and topoisomerase inhibitors are themselves mutagenic and carry a small long-term risk of secondary leukaemias and other malignancies. This is one reason curative regimens are studied carefully to use the least toxic effective dose, especially in children who have decades of life ahead.

Quick Revision

• Cell cycle: G1 → S (DNA synthesis) → G2 → M (mitosis); G0 = resting, protected.
• Antimetabolites act in S phase; vincas/taxanes in M phase; alkylators, platinums, anthracyclines are cell-cycle-nonspecific.
• Log-kill: each dose kills a constant fraction; hence repeated cycles, treatment past remission, and dose intensity matter.
• Combination rules: each drug active alone, different mechanisms, non-overlapping toxicities.
• Targeted therapy blocks a specific driver (imatinib–BCR-ABL, trastuzumab–HER2); needs a companion diagnostic.
• Resistance: efflux (P-glycoprotein), target mutation, DNA repair, apoptosis evasion, reduced uptake/activation.
• Common toxicity: myelosuppression (dose-limiting), mucositis, alopecia, nausea. Signatures: doxorubicin heart, cisplatin kidney/ear, bleomycin lung, vincristine nerve.
• History: mustard gas → nitrogen mustard for lymphoma (Goodman & Gilman, 1942); aminopterin/methotrexate for ALL (Farber, 1947); combination therapy cured childhood ALL (Frei, Freireich, Holland, Skipper, 1960s).

Related Topics

Prerequisites

• Oncology overview
• Pathology — neoplasia, apoptosis, and the cell cycle
• Pharmacology — pharmacokinetics and drug metabolism

Related Topics

• Infectious Diseases — managing febrile neutropenia
• Hematology — leukaemias and marrow suppression

Next Topics

• Radiation therapy principles
• Targeted therapy and immunotherapy in depth
• Oncologic emergencies (tumour lysis syndrome, febrile neutropenia)